[
    [
        {
            "time": "2021-10-26",
            "original_text": "贝莱德10月26日增持11.84万股泰格医药股份，涉资1786.79万港元",
            "features": {
                "keywords": [
                    "贝莱德",
                    "增持",
                    "泰格医药",
                    "11.84万股",
                    "1786.79万港元"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "贝莱德10月26日增持11.84万股泰格医药股份，涉资1786.79万港元",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-29",
            "original_text": "泰格医药(03347.HK)10月29日耗资227.44万元回购1.4万股A股",
            "features": {
                "keywords": [
                    "泰格医药",
                    "回购",
                    "227.44万元",
                    "1.4万股",
                    "A股"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药(03347.HK)10月29日耗资227.44万元回购1.4万股A股",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-10-29",
            "original_text": "【权益变动】泰格医药(03347.HK)被Aggregate of abrdn affiliated investment减持3.47万股",
            "features": {
                "keywords": [
                    "泰格医药",
                    "减持",
                    "3.47万股",
                    "Aggregate of abrdn affiliated investment"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【权益变动】泰格医药(03347.HK)被Aggregate of abrdn affiliated investment减持3.47万股",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10-29",
            "original_text": "中信建投医药大健康团队最新研究",
            "features": {
                "keywords": [
                    "中信建投",
                    "医药",
                    "大健康",
                    "研究"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "大健康"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "中信建投医药大健康团队最新研究",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        }
    ]
]